CDMO is one of the segments of CXO and a hot and booming track in recent years, with its business mainly helping innovative drug companies produce and manufacture new drugs
.
In recent years, with the vigorous development of the global innovative drug industry, the field of pharmaceutical service outsourcing has ushered in greater development opportunities, and the market scale has been expanding
.
The agency predicts that by 2025, the scale of the domestic CDMO industry will exceed the mark of 120 billion yuan, with a compound growth rate of more than 31%.
In the face of such a considerable market, the head enterprise is expected to embrace the opportunity
with its own advantages such as customer resources.
Recently, the head enterprises have made moves, and the layout action has been continuous, including large acquisitions, building bases, and building platforms.
.
.
CDMO head companies have struck! New layout action continues (Source: Pharmaceutical Network)
Puluo Pharmaceutical: Build a global innovative drug service platform
Puluo Pharmaceutical: Build a global innovative drug service platform
Recently, the topping out ceremony of the R&D building of the CDMO global innovative drug service platform project of Puluo Pharmaceutical was successfully held
.
It is reported that the CDMO R&D building covers an area of 2501 square meters, with a total construction area of 13195 square meters, a total of five floors
.
After the completion of the project, it will meet the needs of the CDMO R&D team of more than 500 people in Puluo Pharmaceutical
.
Next, the project is about to enter the interior decoration stage, and the company strives to put it into use
at the end of the first quarter of 2023.
Opram: Capital increase subsidiary
Opram: Capital increase subsidiary
On the evening of September 25, Opmeer issued an announcement that it intends to raise 321 million yuan of IPO funds to increase the capital
of its subsidiary Opmey Bioengineering.
After the completion of this capital increase, the registered capital of Opmey Bioengineering has increased from 170 million yuan to 200 million yuan
.
Opramai said that the purpose of the capital increase is to further strengthen the company's optimization and upgrading in the CDMO business field, further extend the depth and breadth of the CDMO business, and improve the service level of
CDMO biopharmaceutical industrialization.
Kai Laiying: Invested in the construction of a biomedical R&D and production integration base
Kai Laiying: Invested in the construction of a biomedical R&D and production integration base
On the evening of September 26, Kailaiying announced that it intends to invest 4-5 billion yuan to build a biomedical R&D and production integration base project
in Taixing.
The construction of the project is the research and development and production of small molecule CDMO (pharmaceutical contract customized research and development and production, a kind of pharmaceutical outsourcing) chemical raw materials and APIs
.
The company believes that after the signing of the investment agreement, on the one hand, it will rely on the technical advantages and R&D platform advantages accumulated over the years to continuously expand the project pipeline; On the other hand, the company will take advantage of the location advantage of the Yangtze River Delta to accelerate the construction of production capacity, meet the growing demand for orders, expand and deeply participate in the cooperation with domestic and foreign innovative drug companies and biotechnology companies, and strengthen the driving force
of head customers.
Jiuzhou Pharmaceutical: Acquired Zhongshan Preparation Factory under Santox Corporation
Jiuzhou Pharmaceutical: Acquired Zhongshan Preparation Factory under Santox Corporation
On September 27, Kyushu Pharmaceutical announced that the Company decided to use 185 million yuan of the "Four-dimensional Pharmaceutical CDMO Preparation Project" to acquire 100% of the equity of Zhongshan Preparation Factory owned by Sandoz (China) Pharmaceutical Co.
, Ltd.
("Sandoz (China)") and increase its capital
.
For the purpose of the transaction, the Company said it will further strengthen its position
as a core strategic supplier in Novartis' global supply chain.
The target company will serve as the company's high-level CDMO preparation production base, combined with the company's existing API CDMO business advantages and Kangchuanji Pharmaceutical CDMO preparation research and development service capabilities, to promote the company's CDMO API and preparation one-stop business better development
.
Haixiang Pharmaceutical: Investment and construction headquarters research institute
Haixiang Pharmaceutical: Investment and construction headquarters research institute
Haixiang Pharmaceutical announced on the evening of September 26 that the company deliberated and passed the "Proposal on Investment and Construction of Headquarters Research Institute" on the same day, and intends to invest in the construction of the headquarters research institute project in Jiaojiang District, Taizhou City, in order to further enhance the company's comprehensive research and development strength, while expanding CDMO's rapid response capability and the scale of business in
the animal protection sector.
The total investment of the project is expected to be about 300 million yuan (the total investment of the final project is subject to the actual investment), and the construction period is 24 months, and the company will invest in
batches with its own funds or self-raised funds.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.
